Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Anti-cancer composition containing tyrosine kinase inhibitor and alkylating agent

A tyrosine kinase and inhibitor technology, applied in the field of anticancer compositions, can solve the problems of enhanced tolerance, treatment failure and the like

Inactive Publication Date: 2007-11-21
JINAN KANGQUAN PHARMA TECH
View PDF17 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The latter often leads to increased resistance of tumor cells to anticancer drugs, with consequent treatment failure

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0114] Put 80, 80 and 80 mg of p(BHET-EOP / TC) (BHET-EOP: TC is 80: 20) copolymers into three containers of A, B and C respectively, and then add 100 ml of dichloromethane to each , after dissolving and mixing, add 20mg dasatinib, 20mg carmustine, 10mg dasatinib and 10mg carmustine respectively, and prepare 20% dasatinib, 20 % carmustine, and 10% dasatinib and 10% carmustine microspheres for injection. Then suspend the microspheres in physiological saline containing 15% mannitol to prepare the corresponding suspension-type sustained-release injection. The drug release time of the sustained release injection in physiological saline in vitro is 60-70 days, and the drug release time in mouse subcutaneous is more than 60 days.

Embodiment 2

[0116]The method step of being processed into slow-release injection is identical with embodiment 1, but difference is that used auxiliary material is the p(BHET-EOP / TC) of 50: 50, containing anticancer active ingredient and weight percent thereof are:

[0117] (1) 5-40% of Dasatinib or Tipifarnib;

[0118] (2) 1-30% carmustine, nimustine or lomustine; or

[0119] (3) Combination of 5-40% dasatinib or tipifarnib and 1-30% carmustine, nimustine or lomustine.

Embodiment 3

[0121] Put 70 mg of p(LAEG-EOP) with a peak molecular weight of 10,000-25,000 into three containers of A, B, and C, respectively, and then add 100 ml of dichloromethane to each, dissolve and mix well, and pour into the three containers respectively Add 30mg tipifarnib, 30mg carmustine, 20mg tipifarnib and 10mg carmustine, re-shake up and use spray drying method to prepare 30% tipifarnib, 30% carmustine, 20 % Tipifarnib and 10% Carmustine for Injection Microspheres. The dried microspheres are suspended in physiological saline containing 1.5% sodium carboxymethylcellulose to prepare the corresponding suspension-type sustained-release injection. The drug release time of the sustained release injection in physiological saline in vitro is 60-65 days, and the drug release time in mice subcutaneous is about 60 days.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention is concerned with a kind of sustained and controlled release injection of vanticancer compound of depressor with protein tyrosine kinase and / or alkylating agent, relating to sustained and controlled release microsphere and menstruum. The microsphere has effect component and sustained and controlled release assistant stuff form the depressor with protein tyrosine kinase and / or alkylating agent, and the menstruum is common menstruum or special menstruum with assistant suspending agent. The viscosity of assistant suspending agent is 100cp to 3000cp (20 to 30 degree) selecting form Carboxymethylcellulose sodium, and so on. The sustained and controlled release assistant stuff are seleted from the polyphosphate ester copolymer or copolymer of polyphosphate ester and polylactic acid, polystyrene propionic double fatty acids and sebacic acid, copolymer of poly (erucic acid dimmer-sebacic acid) or poly (fumaric acid-sebacic acid), such as p(LAEG-EOP), p(DAPG-EOP), p(BHET-EOP / TC), p( BHET-EOP / TC), p(BHDPT-EOP / TC), p(BHDPT-EOP / TC), p(CHDM-HOP) or p(CHDM-EOP). The anticancer compound is made into sustained and controlled release implant and injects or sets in the tumour or on the round of tumour to maintain the effect concentration over 60 days. It reduces the reaction of whole body greatly and increases the cure effect of nonoperative treatments, such as chemoradiotherapy with selectivity.

Description

(1) Technical field [0001] The invention relates to an anticancer composition containing a tyrosine kinase inhibitor and / or an alkylating agent, which is an anticancer slow-release injection and a slow-release implant, and belongs to the technical field of medicines. (2) Background technology [0002] As a class of commonly used chemotherapeutic drugs, tyrosine kinase inhibitors have been widely used in the treatment of various malignant tumors, and the effect is relatively obvious. However, its significant toxicity greatly limits the wide application of this class of drugs. [0003] Due to the excessive expansion and hyperplasia of solid tumors, the interstitial pressure, tissue elastic pressure, fluid pressure and interstitial viscosity are all higher than those of the surrounding normal tissues. Therefore, it is difficult for conventional chemotherapy to form an effective drug concentration in the tumor. In addition, blood vessels, connective tissue, matrix proteins, fib...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K9/00A61K45/06A61K47/34A61P35/00
Inventor 孙娟张婕邹会凤
Owner JINAN KANGQUAN PHARMA TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com